2022 Fall Conference | C9 - Neurology Update 4: Dementia and Multiple Sclerosis

Date Friday 10/28/22

Time 03:00 PM - 04:30 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Laurie Gutmann, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology, Multiple Sclerosis

Learning Objectives Dementia: Participants should be able to describe contemporary clinical criteria for Alzheimer's disease (AD) and its subtypes; explain the current use of imaging biomarkers for the diagnosis of AD; understand the rationale for cerebrospinal fluid testing in the diagnosis of dementia; outline the potential future use of blood tests in the diagnosis of AD; understand the difference between causal and risk genes for AD; list the major genetic causes of familial frontotemporal dementia and their associated pathologies and imaging findings; list the core diagnostic criteria for Lewy body dementias; understand the major modifiable risk factors for dementia; and name the currently licensed medications for Alzheimer's disease and appreciate the major approaches being tested in clinical trials.
Multiple Sclerosis: After the discussion the listener should be able to describe recent updates in epidemiology of multiple sclerosis; utilize the 2017 McDonald Criteria in order to accurately diagnosis multiple sclerosis; list the best practice guidelines for treating a patient with Radiologically Isolated Syndrome; understand the impact of COVID-19 in persons with MS stratified by their disease course and disease modifying treatment regimen.

CME Available 1.50 CME credits

Core Competencies Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Program Materials

Event Timeline
03:00 PM - 03:45 PM PDT	Speaker	Dementia Jonathan Schott, MD, FRCP, FEAN, FAAN
03:45 PM - 04:30 PM PDT	Speaker	Multiple Sclerosis Michelle Fabian, MD, FAAN

Faculty Disclosures
Laurie Gutmann, MD, FAAN	Dr. Gutmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Gutmann has received research support from NIH. The institution of Dr. Gutmann has received research support from Dyne Therapeutics. Dr. Gutmann has received publishing royalties from a publication relating to health care.
Jonathan Schott, MD, FRCP, FEAN, FAAN	Dr. Schott has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alzheimer's Research UK. Dr. Schott has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UK Dementia Research Institute. Dr. Schott has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Schott has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GE. Dr. Schott has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Oxford University Press.
Michelle Fabian, MD, FAAN	Dr. Fabian has nothing to disclose.

��ɫ��

��ɫ��